HDL CholesterolNCT02554604
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
An observational study of HDL Cholesterol and Preeclampsia, run by Meir Medical Center at 2 sites in Israel.
Trial summary
The study is design to assess if there is a correlation between diagnosis of preeclampsia and its severity to changes in HDL quality, in terms of composition and function and to determine whether preeclampsia-induced changes in VOCs in saliva can be used for the early diagnosis of preeclampsia. Read more about this study
- Who is it for?
- Ages 20 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- HDL Cholesterol, Preeclampsia, Saliva
- How many people
- 30 participants
- Where
- 2 sitesIsrael
- Study dates
- Sep 2015to Sep 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Pregnant woman followed in Community Obstetric Clinics and in the High Risk Obstetric Clinic at Meir Medical Center who agree to participate in the study. Woman will be recruited based on the presence of one or more risk factors for the development of preeclampsia including: first pregnancy, overweight at the beginning of pregnancy or significant weight gain during pregnancy , previous history of preeclampsia and a first degree family member with a history of preeclampsia
Who may be able to join
- Pregnant woman followed in Community Obstetric Clinics and in the High Risk Obstetric Clinic at Meir Medical Center who agree to participate in the study.
- Woman will be recruited based on the presence of one or more risk factors for the development of preeclampsia including: first pregnancy, overweight at the beginning of pregnancy or significant weight gain during pregnancy , previous history of preeclampsia and a first degree family member with a history of preeclampsia.
Who cannot join
- Participants with multiple fetuses (previous medical history of hypertension, chronic kidney disease, diabetes mellitus) or who are unable to provide informed consent due to language barrier or other cause, will be excluded from the study.
- Patients who were not recruited to the study at the beginning of pregnancy will be allowed to join at any stage, including on delivery day.
Trial locations and contacts
2 sites in 1 country.
Israel2 sites
Dr. Yael Einbinder
Kfar Saba
Laboratory of Renal Physiology, Meir Medical Center ,
Kfar Saba
About this study
Official title: Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies and Volatile Organic Compounds in Maternal Saliva Characteristic of Preeclampsia
The study is design to assess if there is a correlation between diagnosis of preeclampsia and its severity to changes in HDL quality, in terms of composition and function and to determine whether preeclampsia-induced changes in VOCs in saliva can be used for the early diagnosis of preeclampsia.
Read the detailed description
Scientific background Preeclampsia is a syndrome characterized by the onset of hypertension and proteinuria or other end-organ dysfunction. It develops after 20 weeks of gestation and can cause significant maternal and fetal morbidity and mortality (1,2). The pathophysiology of preeclampsia is thought to be developmental abnormalities of placental vasculature leading to placental under-perfusion or ischemia. This ischemia is believed to mediate the release of anti-angiogenic factors into the maternal circulation, causing endothelial dysfunction, hypertension and end-organ injury (2). The elemental factor that leads to the development of placental vasculature abnormalities is still to be elucidated. However, histological changes in the placenta include atherosis (lipid laden cells in the wall of the arteriole), fibrinoid necrosis, thrombosis, sclerotic narrowing of arterioles, and placental infarction, all of which are similar to findings seen in atherosclerotic plaque (1-3). Another close association between the mechanisms of preeclampsia and atherosclerosis was found in large epidemiological studies that demonstrated a strong correlation between preeclampsia (PET) and the development of cardiovascular disease later in life (4). Women with PET are more likely than those with normal pregnancy to develop chronic hypertension, cardiovascular disease, stroke, diabetes and end-stage renal disease (1,4).Common atherosclerotic diseases, such as hypertension, chronic kidney disease (CKD), hypercholesterolemia and diabetes are strongly associated with preeclampsia during pregnancy (5-6).
Large epidemiologic and experimental studies have shown an association between low levels of high density lipids (HDL) in the blood and increased cardiovascular risk (7). The cardioprotective properties of HDL are thought to be composed of several mechanisms, including regulation of endothelial functions that enhance NO production and maintaining endothelial integrity, as well as anti-inflammatory, anti-oxidative and anti-thrombotic effects (8-9). However, pharmacological studies reported that increases in plasma HDL did not improve cardiovascular outcomes (10-12).
At the same time, emerging data have revealed the importance of the quality of the HDL more than its quantity. HDL from patients with CKD was found to lose its anti-atherogenic and endothelial protective effects. In a study by Shroff et al. (13), HDL from patients with CKD was incubated with a primary endothelial cell line. Several endothelial functions, such as reduced NO production, permission of SO production, increased VCAM-1 expression and reduction of cholesterol efflux capacity were decreased compared to those of HDL from healthy individuals. These effects were associated with vascular dysfunction markers in those patients, such as high levels of urate, angiopoeitin and IL-6, as well as poor vascular function measurements, as measured by aortic pulse velocity and carotid intima media thickness. These negative functions increased as CKD severity progressed and showed a partial improvement after kidney transplantation (13).
Information regarding the composition and function of serum lipids and lipoproteins among preeclamptic pregnancies compared to normal pregnancies is scarce. Early pregnancy dyslipidemia, particularly hypertriglyceridemia appears to be associated with increased risk of preeclampsia (14). However, equivocal results were found regarding paraoxonase 1 (PON1) activity, which is an antioxidative enzyme found in HDL that inhibits low density lipid (LDL) and HDL oxidation. PON1 activity is decreased in diseases associated with endothelial activation and dysfunction including diabetes, hypercholesterolemia and cardiovascular disease (15). Demir et al. (16) found low levels of HDL, ApoA1 and paraoxonase activity in preeclamptic compared to normal pregnancies, whereas Acikgoz et al. (17) demonstrated significantly higher PON1 activity in preeclamptic compared to normal pregnancies.
Saliva contains constituents that reflect a diseased or physiologic state of the human body and hence could be utilized for diagnostic purposes. The sources and composition of whole saliva (oral fluid) are unique and complex. Saliva consists of secretions from salivary glands and gingival crevicular fluid, oral mucosa transudate, secretions from nasal and pharyngeal mucosa, nonadherent bacteria, desquamated oral epithelial cells, keratin debris, blood cells, and possibly food or medication residuals (18). Its functions include lubrication, digestion, antimicrobial activity, facilitating remineralization of dental enamel, and maintaining normal taste sensation (19). These important functions are achieved by the various chemical components of saliva including water, inorganic compounds (ions), organic compounds (non-proteins and lipids), protein/polypeptides, and hormones (19). The search for reliable salivary biomarkers has developed rapidly, especially in oral cancers, spurred by the fact that collecting saliva is simpler and less invasive than drawing blood.
Salvador-Moysén et al. (20) aimed to determine the usefulness of salivary cortisol as a predictor of preeclampsia in adolescents. They found that cortisol concentrations >14.9 nmol/L were observed in the group that developed preeclampsia, whereas the control group had values <10.1 nmol/L.
Volatile organic compounds (VOC) can be detected in the breath and blood and used for the early detection and characterization of the development and progression of diseases (21). Many of the VOC that are detected in the breath are systemic or endogenous and are produced during physiological processes, but the metabolic routes behind their production are known for only a few (22). Other VOCs are exogenous and result from external contamination through inhaled air or ingested foods or drinks.
Solid phase microextraction (SPME) is a simple, automated, rapid technique for VOC detection combined with gas chromatography-mass spectrometry (GC-MS) (20). To the best of our knowledge, no studies have been conducted to identify VOC in saliva from preeclamptic women.
Objectives
- There is a correlation between diagnosis of preeclampsia and its severity to changes in HDL quality, in terms of composition and function.
- Determine whether preeclampsia-induced changes in VOCs in saliva can be used for the early diagnosis of preeclampsia.
Research goals
- Assess: HDL composition and function of normal and preeclamptic pregnancies at weeks 12-14 (second trimester), weeks 28-30 (third trimester) and at delivery Apo-A1 properties, PON1 activity HDL size HDL lipid content HDL antioxidant activity (toward LDL and macrophages) HDL-mediated cholesterol efflux from macrophages
- Evaluate the effects of HDL from women with PET, normal pregnancies and non-pregnant women, on primary endothelial culture regarding proteins, mRNA and miRNAs, which are significant components in normal endothelial function and related to inflammatory response.
- Evaluate differences in the genomic and lipid profiles of cord blood and placentas from women with PET, normal pregnancies and non-pregnant women
- Identify VOC in saliva, as early biomarkers of PET during the second and third trimesters and at delivery.
- Conditions
- HDL Cholesterol, Preeclampsia, Saliva
- Keywords
- HDL, Preeclampsia, saliva
- Medical subject headings
- Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant woman | Pregnant woman with identified risk factors for the development of preeclampsia |
What is being measured
The primary outcome is the main question the study is designed to answer.
signs and symptoms of preeclampsia
blood pressure, BMI, presence of edema, urinalysis-proteinuria, in addition to all routine second and third trimester checkups that will be documented.
Measured: 9 months
Secondary outcomes (1)
Blood samples for lipid profile and HDL
blood samples will be collected from the volunteers during their pregnancy follow up during the first trimester 12-14 weeks, second trimester 28-32 weeks and on delivery day.
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2015 (estimated)
- Study startSep 2015
- Primary completionSep 2018
- Study completionSep 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HDL CholesterolStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Meir Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, yael einbinder, Meir Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02554604
- Sponsor's protocol ID
- 0122-15
- Status last verified
- Aug 2018
- First submitted
- 17 Sep 2015
- Last updated
- 9 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies and Volatile Organic Compounds in Maternal Saliva Characteristic of Preeclampsia
- ClinicalTrials.gov ID
- NCT02554604
- Acronym / sponsor ID
- 0122-15
- Conditions
- HDL Cholesterol, Preeclampsia, Saliva
- Keywords
- HDL, Preeclampsia, saliva
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Meir Medical CenterUniversity, hospital or other
- Study start
- Sep 2015
- Primary completion
- Sep 2018 (actual)
- Study completion
- Sep 2018 (actual)
- First posted
- 18 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is design to assess if there is a correlation between diagnosis of preeclampsia and its severity to changes in HDL quality, in terms of composition and function and to determine whether preeclampsia-induced changes in VOCs in saliva can be used for the early diagnosis of preeclampsia.
Detailed description
Scientific background Preeclampsia is a syndrome characterized by the onset of hypertension and proteinuria or other end-organ dysfunction. It develops after 20 weeks of gestation and can cause significant maternal and fetal morbidity and mortality (1,2). The pathophysiology of preeclampsia is thought to be developmental abnormalities of placental vasculature leading to placental under-perfusion or ischemia. This ischemia is believed to mediate the release of anti-angiogenic factors into the maternal circulation, causing endothelial dysfunction, hypertension and end-organ injury (2). The elemental factor that leads to the development of placental vasculature abnormalities is still to be elucidated. However, histological changes in the placenta include atherosis (lipid laden cells in the wall of the arteriole), fibrinoid necrosis, thrombosis, sclerotic narrowing of arterioles, and placental infarction, all of which are similar to findings seen in atherosclerotic plaque (1-3). Another close association between the mechanisms of preeclampsia and atherosclerosis was found in large epidemiological studies that demonstrated a strong correlation between preeclampsia (PET) and the development of cardiovascular disease later in life (4). Women with PET are more likely than those with normal pregnancy to develop chronic hypertension, cardiovascular disease, stroke, diabetes and end-stage renal disease (1,4).Common atherosclerotic diseases, such as hypertension, chronic kidney disease (CKD), hypercholesterolemia and diabetes are strongly associated with preeclampsia during pregnancy (5-6).
Large epidemiologic and experimental studies have shown an association between low levels of high density lipids (HDL) in the blood and increased cardiovascular risk (7). The cardioprotective properties of HDL are thought to be composed of several mechanisms, including regulation of endothelial functions that enhance NO production and maintaining endothelial integrity, as well as anti-inflammatory, anti-oxidative and anti-thrombotic effects (8-9). However, pharmacological studies reported that increases in plasma HDL did not improve cardiovascular outcomes (10-12).
At the same time, emerging data have revealed the importance of the quality of the HDL more than its quantity. HDL from patients with CKD was found to lose its anti-atherogenic and endothelial protective effects. In a study by Shroff et al. (13), HDL from patients with CKD was incubated with a primary endothelial cell line. Several endothelial functions, such as reduced NO production, permission of SO production, increased VCAM-1 expression and reduction of cholesterol efflux capacity were decreased compared to those of HDL from healthy individuals. These effects were associated with vascular dysfunction markers in those patients, such as high levels of urate, angiopoeitin and IL-6, as well as poor vascular function measurements, as measured by aortic pulse velocity and carotid intima media thickness. These negative functions increased as CKD severity progressed and showed a partial improvement after kidney transplantation (13).
Information regarding the composition and function of serum lipids and lipoproteins among preeclamptic pregnancies compared to normal pregnancies is scarce. Early pregnancy dyslipidemia, particularly hypertriglyceridemia appears to be associated with increased risk of preeclampsia (14). However, equivocal results were found regarding paraoxonase 1 (PON1) activity, which is an antioxidative enzyme found in HDL that inhibits low density lipid (LDL) and HDL oxidation. PON1 activity is decreased in diseases associated with endothelial activation and dysfunction including diabetes, hypercholesterolemia and cardiovascular disease (15). Demir et al. (16) found low levels of HDL, ApoA1 and paraoxonase activity in preeclamptic compared to normal pregnancies, whereas Acikgoz et al. (17) demonstrated significantly higher PON1 activity in preeclamptic compared to normal pregnancies.
Saliva contains constituents that reflect a diseased or physiologic state of the human body and hence could be utilized for diagnostic purposes. The sources and composition of whole saliva (oral fluid) are unique and complex. Saliva consists of secretions from salivary glands and gingival crevicular fluid, oral mucosa transudate, secretions from nasal and pharyngeal mucosa, nonadherent bacteria, desquamated oral epithelial cells, keratin debris, blood cells, and possibly food or medication residuals (18). Its functions include lubrication, digestion, antimicrobial activity, facilitating remineralization of dental enamel, and maintaining normal taste sensation (19). These important functions are achieved by the various chemical components of saliva including water, inorganic compounds (ions), organic compounds (non-proteins and lipids), protein/polypeptides, and hormones (19). The search for reliable salivary biomarkers has developed rapidly, especially in oral cancers, spurred by the fact that collecting saliva is simpler and less invasive than drawing blood.
Salvador-Moysén et al. (20) aimed to determine the usefulness of salivary cortisol as a predictor of preeclampsia in adolescents. They found that cortisol concentrations >14.9 nmol/L were observed in the group that developed preeclampsia, whereas the control group had values <10.1 nmol/L.
Volatile organic compounds (VOC) can be detected in the breath and blood and used for the early detection and characterization of the development and progression of diseases (21). Many of the VOC that are detected in the breath are systemic or endogenous and are produced during physiological processes, but the metabolic routes behind their production are known for only a few (22). Other VOCs are exogenous and result from external contamination through inhaled air or ingested foods or drinks.
Solid phase microextraction (SPME) is a simple, automated, rapid technique for VOC detection combined with gas chromatography-mass spectrometry (GC-MS) (20). To the best of our knowledge, no studies have been conducted to identify VOC in saliva from preeclamptic women.
Objectives
- There is a correlation between diagnosis of preeclampsia and its severity to changes in HDL quality, in terms of composition and function.
- Determine whether preeclampsia-induced changes in VOCs in saliva can be used for the early diagnosis of preeclampsia.
Research goals
- Assess: HDL composition and function of normal and preeclamptic pregnancies at weeks 12-14 (second trimester), weeks 28-30 (third trimester) and at delivery Apo-A1 properties, PON1 activity HDL size HDL lipid content HDL antioxidant activity (toward LDL and macrophages) HDL-mediated cholesterol efflux from macrophages
- Evaluate the effects of HDL from women with PET, normal pregnancies and non-pregnant women, on primary endothelial culture regarding proteins, mRNA and miRNAs, which are significant components in normal endothelial function and related to inflammatory response.
- Evaluate differences in the genomic and lipid profiles of cord blood and placentas from women with PET, normal pregnancies and non-pregnant women
- Identify VOC in saliva, as early biomarkers of PET during the second and third trimesters and at delivery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant woman | – | –Pregnant woman with identified risk factors for the development of preeclampsia |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Pregnant woman followed in Community Obstetric Clinics and in the High Risk Obstetric Clinic at Meir Medical Center who agree to participate in the study. Woman will be recruited based on the presence of one or more risk factors for the development of preeclampsia including: first pregnancy, overweight at the beginning of pregnancy or significant weight gain during pregnancy , previous history of preeclampsia and a first degree family member with a history of preeclampsia
Key inclusion criteria (2 listed)
- Pregnant woman followed in Community Obstetric Clinics and in the High Risk Obstetric Clinic at Meir Medical Center who agree to participate in the study.
- Woman will be recruited based on the presence of one or more risk factors for the development of preeclampsia including: first pregnancy, overweight at the beginning of pregnancy or significant weight gain during pregnancy , previous history of preeclampsia and a first degree family member with a history of preeclampsia.
Key exclusion criteria (2 listed)
- Participants with multiple fetuses (previous medical history of hypertension, chronic kidney disease, diabetes mellitus) or who are unable to provide informed consent due to language barrier or other cause, will be excluded from the study.
- Patients who were not recruited to the study at the beginning of pregnancy will be allowed to join at any stage, including on delivery day.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
signs and symptoms of preeclampsia
Time frame: 9 months
blood pressure, BMI, presence of edema, urinalysis-proteinuria, in addition to all routine second and third trimester checkups that will be documented.
1 secondary outcome
Blood samples for lipid profile and HDL
Time frame: 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for HDL Cholesterol
Not yet recruitingObservational study
Metabolic and Inflammatory Indices in Lateral Epicondylitis
Lateral Epicondylitis
Not yet recruiting
Goji Berry and Vasomotor Symptoms Pilot Study
Vasomotor Symptoms
Not yet recruiting
Fish Oil and HDL Function in Patients on Maintenance Hemodialysis
Kidney Failure Chronic, Cardiovascular Disease
Recruiting
Effects of Goji vs. Fiber on Macular Degeneration
Age-Related Macular Degeneration
Recruiting
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
Prediabetes, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HDL Cholesterol and Preeclampsia, run by Meir Medical Center at 2 sites in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
signs and symptoms of preeclampsia (time frame: 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2019.